Franck Molina, Montpellier, France

Franck.molina@sysdiag.cnrs.fr

http://sysdiag.cnrs.fr

Private Public collaboration to boost open innovation

Diagnostic in mutation

+5-6%

+14-15%

Change of paradigm with the

convergence of diagnosis and

therapy, going to personalized

medecine and theranostic

New role of biomarker in biomedical

and therapeutic, molecular assay

development (nucleic acid,

proteines, metabolites)

explosion of POC Technologies and

of home monitoring/testing)

Integration with IT

New interfaces electronic/biology

(Biosensor)

An

nu

al

ma

rke

r b€

Diagnostic tests represent less than 5% of hospital cost

and about 1.6 % of all health cost. Their results influence

up to 60-70% medical decision”

Source = The Lewin Group, Inc., The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care,July 2005

+8%

Clinical

question Biomarkers

Where is performed the test

Who is taking the decision

Direct Cost

Undirect Cost

reliability

Mobility / miniaturization

Communication

Remote control

Screening

Diagnosis

Monitoring

Companion test

Medical

Device

Ethic

Security

Juridic

Coupling Biology with electronics

Biosensors

Translational Medicine

Diagnostic / Personnalized medicine

innovation is highly interdisciplinary scientific :

biology, biochemistry, genetic

chemistry

physic

mathematic

computing

robotic

Etc.

medical

medecine

clinic

pharmacology

etc.

business

Business strategy / IP

Finance

Socio-economic impact

Marketing

Regulation

Sales

Ethics

Business

motivation

Scientist

motivation

Reduce possibilities

Increase possibilities

Reduce possibilities

Crossing disciplines for innovation in Diagnosis

Combining experimental biology and complex systems modelling approaches

70% experimentalists and 30% theoreticians

The SysDiag model Public / private mix and interdisciplinary

SysDiag’s missions are : • to understand the bases of chronic and multifactorial diseases (neurodegenerative and cardiovascular diseases, cancer, diabetes...) • to identify new biomarkers associated with these pathological conditions • to provide innovative solutions for clinicians that will contribute to improve the health and quality of life of their patients.

Dicovery innovation Industrial Transfert R/D Production

Eurobiomed, Southern French Health cluster

Medicen Paris

CancerBioSanté Toulouse

LyonBioPôle Lyon

Alsace Biovalley Starsbourg

Eurobiomed Marseille

French health clusters

Smart-specialization in medical Diagnosis

Eurobiomed Mission Eurobiomed Added Value

Develop Life science potential via dedicated and adapted working

groups: Euromediag,

Ophtabiotech…

- Develop and federate a network of healthcare

stakeholders - Provide development support

for companies - Foster the implementation of

R&D collaborative projects

Eurobiomed Sharing

Strong international cooperation network in:

- Diagnostics access to 350 SME in EU

- Neurorescue EU Neuroscience community

To support

400 companies

4 science & technology parks

Over 6000 academic

researchers

3000 industrial researchers

4 top-ranked universities

Eurobiomed : to create value and employment

Networking Companies’

Growth Transnational

project support Market access

R&D

partnership /

platform Innovation/

funding/

regulatory/

HR

International

development

Events

From innovation

to patient

benefit

Build and manage

a network of In

Vitro diagnostic

experts

Contribute to the

economic

development of

these regions

Spain

Scotland

Canada

India

China

Poland

US

England

Germany

Sweden

European

diagnostic

cluster

Alliance

>350 SMEs

Wales

European Diagnostic Cluster Alliance

Brasil

WP1 Organization/structure/Funding (short term)

Main Resp. EuroMediag, Vice-resp: Wal-Dx

WP2 Mapping/Sharing expertise (DB) (short term)

Main Resp. Wal-Dx Vice-resp: Krakow

WP3 Access to the market/SME growth (long term)

Reshaping Diag Market/Practices…

Main Resp. OBN, Vice-resp: Nexxus, Uppsala Bio

WP4 Cooperation Model Comp/Acad/Clinic

Main Resp.ZMDB Vice-resp: BioCat

Support from:

T. PETRIN, European Cluster Policy Group

EDCA implementation

Market Reshaping ?

Patient Individual Behavior

Clinician Decision

Patient benefit

Diag / MD Industry

Pharma Industry

Laboratories test

Clinician Prescrition

treatment

Clinician Needs

Alternative routes to consumers New practices

New technologies New regulatory issues

Etc.

Room for innovation New innovative actors to come into the field

Patient centred strategies Research

Patient associations

What do we need ?

Open-innovation targeting : - Individual or close to the patient market New technologies (@health), niche innovation, Mainly inspired by patient demand or new clinical practices Interdisciplinary partnership, SMEs growth opportunities - Specialized laboratory asssay market Heavy technology, Mainly inspired by clinician demand

large public/private consortia (including pharma),

To run/support international pionner projets able to induce : market reshaping (new clinical practices) European « Patient Leadership »

Early and dynamic interaction between innovation and Regulation

More than 350 reachable compagnies

Network of technological platforms

A set of international partnership events

Scientific, Clinical and Regulation expertise